Trevena Inc (TRVN)

$0.28 -0.01 (-1.79%)
Market Cap 268,000.00
Revenue (ttm) 3.13M
Net Income (ttm) -40.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,287.22%
Debt to Equity Ratio -1.41
Volume 800
Avg Vol 1,512
Day's Range N/A - N/A
Shares Out 959,000.00
Stochastic %K 4%
Beta 0.41
Analysts Hold
Price Target $5.00

Company Profile

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic p...

Industry: Biotechnology
Sector: Healthcare
Phone: 610 354 8840
Address:
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, United States
JosephinePhillips1015
JosephinePhillips1015 Aug. 18 at 2:41 PM
$TRVN trades like a typical development-stage biotech, waiting on catalysts. KLTO provided its own spark by starting production on KLTO-202 with a stronger partner.
0 · Reply
Primetime11112
Primetime11112 Aug. 18 at 2:04 PM
$TRVN rumor is at the water cooler that they are going to file bankruptcy. Now you know.
1 · Reply
Inspector510
Inspector510 Aug. 16 at 2:45 AM
$TRVN Have a great weekend everyone!! God bless all of you!!
1 · Reply
MadMaverick
MadMaverick Aug. 15 at 4:33 PM
$RNXT – Take a Look at This 💥👇 Fundamental Highlights: ✅Q2 2025 EPS: –$0.08 (beat estimate of –$0.09) ✅Revenue: $422K (vs. $288K expected) ✅Commercial rollout to 13 cancer centers using RenovoCath Competitive Edge: - Phase III trials targeting locally advanced pancreatic cancer - Expanding commercial footprint alongside clinical progress - Insider confidence: CMO purchased ~$29K worth of shares recently TA: Strong Demand down in this zone! Overall, this signals a company showing early financial improvement, growing market reach, and strong insider confidence, factors that could drive long-term growth if clinical goals are achieved. Communicated Disclaimer: https://chartingdaily.com/RenovoRx-Outlook-and-Clinical-Progress Other names in the same sector: $CRDF $GERN $TRVN $ARCT
0 · Reply
bbcontroll
bbcontroll Aug. 5 at 9:38 AM
$TRVN 💩💩💩💩💩
0 · Reply
zsk78
zsk78 Aug. 4 at 7:01 PM
$TRVN 🧐
0 · Reply
Trak2
Trak2 Jul. 30 at 8:10 PM
$TRVN any chance we can get money back from any lawsuits?
1 · Reply
End00Game
End00Game Jul. 26 at 1:56 AM
$TRVN This is a opportunity to sit and wait patient for a good drop on $IBB if you want to gamble on stocks. Sell this trash now if you still have it
0 · Reply
M592018
M592018 Jul. 24 at 11:19 PM
$TRVN
0 · Reply
TravisA9
TravisA9 Jul. 17 at 1:44 PM
$TRVN Hope all are well here! So do they just sit on pink sheets for eternity as a zombie company and continue zero fiduciary responsibility to shareholders or will R-Bridge finally force their hands on the loan? We, as shareholders, are still paying people to literally do nothing, please prove me wrong if possible. There are many companies in a similar situation. I believe the market is fundamentally and systematically broken in many ways, this situation being a great example. I don’t have a perfect answer but whatever this is, certainly isn’t it. They should not be allowed to continue to “operate”, — TRVN should be forced into bankruptcy or liquid/sell every asset remaining. In its current status, there’s no way TRVN can be considered a “public” company. It’s wild this PR on TRV045 was less than 1 year ago and poof, not a thing since. https://www.trevena.com/investors/press-releases/detail/343/trevena-reports-second-quarter-2024-results-and-provides-business-update
3 · Reply
Latest News on TRVN
No data available.
JosephinePhillips1015
JosephinePhillips1015 Aug. 18 at 2:41 PM
$TRVN trades like a typical development-stage biotech, waiting on catalysts. KLTO provided its own spark by starting production on KLTO-202 with a stronger partner.
0 · Reply
Primetime11112
Primetime11112 Aug. 18 at 2:04 PM
$TRVN rumor is at the water cooler that they are going to file bankruptcy. Now you know.
1 · Reply
Inspector510
Inspector510 Aug. 16 at 2:45 AM
$TRVN Have a great weekend everyone!! God bless all of you!!
1 · Reply
MadMaverick
MadMaverick Aug. 15 at 4:33 PM
$RNXT – Take a Look at This 💥👇 Fundamental Highlights: ✅Q2 2025 EPS: –$0.08 (beat estimate of –$0.09) ✅Revenue: $422K (vs. $288K expected) ✅Commercial rollout to 13 cancer centers using RenovoCath Competitive Edge: - Phase III trials targeting locally advanced pancreatic cancer - Expanding commercial footprint alongside clinical progress - Insider confidence: CMO purchased ~$29K worth of shares recently TA: Strong Demand down in this zone! Overall, this signals a company showing early financial improvement, growing market reach, and strong insider confidence, factors that could drive long-term growth if clinical goals are achieved. Communicated Disclaimer: https://chartingdaily.com/RenovoRx-Outlook-and-Clinical-Progress Other names in the same sector: $CRDF $GERN $TRVN $ARCT
0 · Reply
bbcontroll
bbcontroll Aug. 5 at 9:38 AM
$TRVN 💩💩💩💩💩
0 · Reply
zsk78
zsk78 Aug. 4 at 7:01 PM
$TRVN 🧐
0 · Reply
Trak2
Trak2 Jul. 30 at 8:10 PM
$TRVN any chance we can get money back from any lawsuits?
1 · Reply
End00Game
End00Game Jul. 26 at 1:56 AM
$TRVN This is a opportunity to sit and wait patient for a good drop on $IBB if you want to gamble on stocks. Sell this trash now if you still have it
0 · Reply
M592018
M592018 Jul. 24 at 11:19 PM
$TRVN
0 · Reply
TravisA9
TravisA9 Jul. 17 at 1:44 PM
$TRVN Hope all are well here! So do they just sit on pink sheets for eternity as a zombie company and continue zero fiduciary responsibility to shareholders or will R-Bridge finally force their hands on the loan? We, as shareholders, are still paying people to literally do nothing, please prove me wrong if possible. There are many companies in a similar situation. I believe the market is fundamentally and systematically broken in many ways, this situation being a great example. I don’t have a perfect answer but whatever this is, certainly isn’t it. They should not be allowed to continue to “operate”, — TRVN should be forced into bankruptcy or liquid/sell every asset remaining. In its current status, there’s no way TRVN can be considered a “public” company. It’s wild this PR on TRV045 was less than 1 year ago and poof, not a thing since. https://www.trevena.com/investors/press-releases/detail/343/trevena-reports-second-quarter-2024-results-and-provides-business-update
3 · Reply
IzzyMoney810
IzzyMoney810 Jul. 15 at 4:07 PM
$TRVN How the hell did this POS manage to return to trading OTC again???
0 · Reply
Inspector510
Inspector510 Jul. 11 at 11:18 PM
$TRVN Have a Spirit led weekend everyone!! God bless all of you!!
0 · Reply
Primetime11112
Primetime11112 Jul. 9 at 4:09 PM
$TRVN
0 · Reply
Kaltycoon
Kaltycoon Jul. 8 at 10:14 PM
$TRVN this is military grade stuff, the US government needs to step in and buy it since it’s already printing money and spending it there 10x from here
0 · Reply
Ueberschlaefer
Ueberschlaefer Jul. 2 at 8:18 PM
$TRVN went to OTC finally after destroying 1+ billion. the loans for 500 million can never be paid back ever. however, to their credit, they produced an FDA approved retail product that had positive remarks. it was simply ridiculously priced when compared against generics. last i read, they were trying to sell in china. actually a useable and needed therapeutic even if irrelevant and too expensive. $GOVX has produced nothing besides PRs and Zach's Research garbage posts here.
2 · Reply
M592018
M592018 Jun. 30 at 9:38 PM
$TRVN
0 · Reply
bbcontroll
bbcontroll Jun. 30 at 2:06 PM
$TRVN 💩💩💩💩
0 · Reply
SatoshiChrist
SatoshiChrist Jun. 28 at 3:33 PM
$TRVN I got my ass handed to me on this, and one of my friends did too, the weird part is, olinvyk has crazy amounts of potential.. some argue that because morphine is less expensive that no one will use olinvyk. I would argue that people spend money on stupid shit all the time. Why not spend a lil more on a pain medicine with less side effects
3 · Reply
Inspector510
Inspector510 Jun. 27 at 9:45 PM
$TRVN Have a wonderful weekend!! God bless all of you and your families!!
1 · Reply
Clifden
Clifden Jun. 25 at 9:17 PM
$ANVS Maybe Maria can hire Carrie Bourdow from $TRVN. She has experience running biotechs into the ground. Just ask the Hobbit man !! And yes , I lost some cake here after holding far too long . GLTA
2 · Reply
ZhaoSonsWealth
ZhaoSonsWealth Jun. 20 at 2:39 AM
GLMD is sitting on a launchpad. Under cash, no debt, real GLP-1/fibrosis catalysts, and a float that already sent it to $2.08 without news. The setup is rare and it’s ready. $SHPH $TRVN $IMRN $TIVC
0 · Reply
KhalidsCapital
KhalidsCapital Jun. 20 at 12:03 AM
GLMD Still under the radar. $12+ book, no debt, no dilution, and billion-dollar GLP-1 catalysts approaching. These are the trades that change lives. $ACHV $TRVN $RWLK $LIXT
2 · Reply